As the biopharmaceutical industry continues to prioritize precision and purity, material suppliers are adopting increasingly rigorous standards to combat particle contamination. Unwanted particulates in drug products, especially injectables, can lead to significant economic losses and, more importantly, pose serious risks to patient safety. Effective mitigation requires collaboration with partners who possess deep expertise in contamination control. Drawing on its heritage in the semiconductor industry, Entegris applies an exceptional level of sensitivity to purity and particle management, supported by robust quality systems, advanced contamination control technologies, and proprietary detection and sizing platforms. This paper examines the lifecycle of particle contamination in biomanufacturing and highlights practical strategies to mitigate its effects.
